Loading…
Loading…
CMVLF (Cellectis S.A.) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
CMVLF does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for CMVLF and 80,000+ other tickers.
See exactly how CMVLF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for CMVLF and 80,000+ other tickers.
Cellectis S.A. is a clinical-stage biotechnology firm dedicated to advancing immuno-oncology therapies. Their core technology involves engineering T-cells with gene editing to express chimeric antigen receptors (CARs), enabling these modified cells to precisely target and destroy cancer cells. The company's operations are structured into two principal divisions: Therapeutics and Plants. Its robust development pipeline includes several crucial product candidates. Notable among these is UCART19, an allogeneic T-cell treatment designed for CD19-expressing blood cancers like acute lymphoblastic…
No recent news available.